Medical Pharmaceuticals

August 12, 2026

Together, the two companies give physicians a single platform to measure biological insights, deliver personalized interventions, and demonstrate…

HHealthcare

July 17, 2026

AtaiBeckley’s lead program, BPL-003, is designed to provide durable relief from treatment-resistant depression Acquisition expands Lilly’s neuroscience pipeline…

HHealthcare

Septa Pharmaceuticals Inc. Acquires CeeNU® (Lomustine) from Bristol Myers Squibb, Canada

July 15, 2026

Mississauga, ON, July 15, 2026 /PRNewswire/ – Septa Pharmaceuticals Inc., a rapidly growing leader in the Canadian healthcare…

MMental health

June 21, 2026

More than 1 in 4 employees report low well-being, according to a new report from WebMD Health Services. PORTLAND, Ore., June 18,…

HHealth

June 17, 2026

National Campaign Explores Advances in Early Detection, Research, Caregiving, and Brain Health NEW YORK, June 17, 2026 /PRNewswire/…

HHealth

June 10, 2026

ATLANTA, June 10, 2026 /PRNewswire/ — Huxley Medical, a commercial-stage medical technology company expanding access to sleep apnea…

BBusiness

Wegovy® pill prescriptions surpass 3 million, 1 filled roughly every 5 seconds, bringing GLP-1 therapy to people with obesity previously untreated, while Novo Nordisk unveils new data at ADA 2026

June 7, 2026

Three million prescriptions for Wegovy® pill since launch on January 5th serves as another milestone in one of…

HHealth

June 6, 2026

New analysis supports DNlite™ for earlier renal risk stratification in patients with type 2 diabetes and chronic kidney…

HHealth

First Dual GLP-1/GIP Receptor Agonist Developed for Type 1 Diabetes Shows Promising Benefits in Blood Glucose Control

June 5, 2026

Phase 2 Study Results Highlight Use of Once-Daily Injection for Weight Loss and Reduction in Insulin Use NEW…

MMedication

Novo Nordisk Introduces Extra Savings for Canadians Who Choose Ozempic®

May 26, 2026

MISSISSAUGA, ON, May 26, 2026 /CNW/ – Novo Nordisk Canada is announcing that effective Friday, May 29, 2026,…

HHealthcare

Vi Launches Suite of AI Agents for Healthcare, Life Sciences, and Wellness Enterprises; Completes $145M Transaction at $1.64B Valuation

May 20, 2026

NEW YORK, May 19, 2026 /PRNewswire/ — Vi, the enterprise-AI platform for health, today announced a new suite…

MMedication

May 17, 2026

In ATTAIN-MAINTAIN, participants who transitioned from a maximum tolerated dose (MTD) of Wegovy (semaglutide) to Foundayo maintained all…

Viome Acquires Circulate Health, Closing the Loop Between Early Diagnostics, Precision Nutrition, and Treatment

Lilly to acquire AtaiBeckley to advance therapies for treatment-resistant depression and other mental health conditions

Septa Pharmaceuticals Inc. Acquires CeeNU® (Lomustine) from Bristol Myers Squibb, Canada

Employee Well-Being Slips as Financial Stress Surges, Survey Finds

Huxley Medical Expands SANSA Diagnostic Platform with Point-of-Care Enrollment and Additional Cardiovascular Risk Marker

Wegovy® pill prescriptions surpass 3 million, 1 filled roughly every 5 seconds, bringing GLP-1 therapy to people with obesity previously untreated, while Novo Nordisk unveils new data at ADA 2026

Bio Preventive Medicine and Precision Diabetes Announce ADA Late-Breaking Presentation Highlighting DNlite™ in Landmark CREDENCE Trial

First Dual GLP-1/GIP Receptor Agonist Developed for Type 1 Diabetes Shows Promising Benefits in Blood Glucose Control

Novo Nordisk Introduces Extra Savings for Canadians Who Choose Ozempic®

Vi Launches Suite of AI Agents for Healthcare, Life Sciences, and Wellness Enterprises; Completes $145M Transaction at $1.64B Valuation

Lilly’s Foundayo and lower-dose Zepbound helped people maintain weight loss after switching from higher doses of injectable incretin therapy in two late-phase trials